| Target Price | kr285.60 |
| Price | kr291.00 |
| Deviation |
1.86%
register free of charge
|
| Number of Estimates | 8 |
|
8 Analysts have issued a price target BioArctic AB 2026 .
The average BioArctic AB target price is kr285.60.
This is
1.86%
register free of charge
kr370.65
27.37%
register free of charge
kr222.20
23.64%
register free of charge
|
|
| A rating was issued by 9 analysts: 7 Analysts recommend BioArctic AB to buy, 1 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the BioArctic AB stock has an average upside potential 2026 of
1.86%
register free of charge
|
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Billion kr | 0.26 | 2.01 |
| 58.22% | 681.43% | |
| EBITDA Margin | -82.15% | 60.32% |
| 278.81% | 173.42% | |
| Net Margin | -68.81% | 51.40% |
| 284.89% | 174.70% |
5 Analysts have issued a sales forecast BioArctic AB 2025 . The average BioArctic AB sales estimate is
This results in the following potential growth metrics:
4 Analysts have issued an BioArctic AB EBITDA forecast 2025. The average BioArctic AB EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
5 BioArctic AB Analysts have issued a net profit forecast 2025. The average BioArctic AB net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share kr | -2.00 | 11.68 |
| 177.22% | 684.00% | |
| P/E | 24.92 | |
| EV/Sales | 11.92 |
5 Analysts have issued a BioArctic AB forecast for earnings per share. The average BioArctic AB EPS is
This results in the following potential growth metrics and future valuations:
| Analyst | Rating | Action | Date |
|---|---|---|---|
| RX SECURITIES |
Locked
➜
Locked
|
Locked | Sep 01 2025 |
| RX SECURITIES |
Locked
➜
Locked
|
Locked | May 21 2025 |
| RX SECURITIES |
Locked
➜
Locked
|
Locked | May 20 2025 |
| RX SECURITIES |
Locked
➜
Locked
|
Locked | Mar 25 2025 |
| RX SECURITIES |
Locked
➜
Locked
|
Locked | Mar 24 2025 |
| DNB CARNEGIE |
Locked
➜
Locked
|
Locked | Feb 16 2025 |
| DNB MARKETS |
Locked
➜
Locked
|
Locked | Feb 16 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
RX SECURITIES:
Locked
➜
Locked
|
Sep 01 2025 |
|
Locked
RX SECURITIES:
Locked
➜
Locked
|
May 21 2025 |
|
Locked
RX SECURITIES:
Locked
➜
Locked
|
May 20 2025 |
|
Locked
RX SECURITIES:
Locked
➜
Locked
|
Mar 25 2025 |
|
Locked
RX SECURITIES:
Locked
➜
Locked
|
Mar 24 2025 |
|
Locked
DNB CARNEGIE:
Locked
➜
Locked
|
Feb 16 2025 |
|
Locked
DNB MARKETS:
Locked
➜
Locked
|
Feb 16 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


